Literature DB >> 21495968

NF-κB in type 1 diabetes.

Yuxing Zhao1, Balasubramanian Krishnamurthy, Zia U A Mollah, Thomas W H Kay, Helen E Thomas.   

Abstract

Type 1 diabetes is an autoimmune disease in which pancreatic beta cells are destroyed by autoreactive T cells. It is a common pediatric disease with increasing incidence. Islet transplantation may be a therapeutic option, however, the current limitations of this procedure mean that for most sufferers of type 1 diabetes there is no cure. The transcription factor NF-κB has been widely studied for its role in development of type 1 diabetes. Recent data have shown that NF-κB is required for activation of autoreactive T cells, and its hyperactivity in monocytes and dendritic cells results in altered cytokine secretion and antigen presentation, which ultimately contributes to the initiation of type 1 diabetes. NF-κB is also activated by a number of proinflammatory cytokines to regulate both the survival and death of beta cells. The critical role of NF-κB in type 1 diabetes renders it a promising pharmaceutical target in the intervention of this disease and further understanding of the NF-κB pathway will have an important implication on the development of novel and safe therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21495968     DOI: 10.2174/187152811795564046

Source DB:  PubMed          Journal:  Inflamm Allergy Drug Targets        ISSN: 1871-5281


  19 in total

1.  NF-κB in DCs: it takes effort to be immature.

Authors:  Rémi J Creusot
Journal:  Nat Med       Date:  2011-12-06       Impact factor: 53.440

2.  Genetic variations in the PSMA3, PSMA6 and PSMC6 genes are associated with type 1 diabetes in Latvians and with expression level of number of UPS-related and T1DM-susceptible genes in HapMap individuals.

Authors:  Tatjana Sjakste; Natalia Paramonova; Kristine Osina; Kristine Dokane; Jelizaveta Sokolovska; Nikolajs Sjakste
Journal:  Mol Genet Genomics       Date:  2015-12-12       Impact factor: 3.291

Review 3.  Lessons from the mouse: potential contribution of bystander lymphocyte activation by viruses to human type 1 diabetes.

Authors:  Jessica A Pane; Barbara S Coulson
Journal:  Diabetologia       Date:  2015-03-21       Impact factor: 10.122

4.  Pioglitazone, extract of compound Danshen dripping pill, and quercetin ameliorate diabetic nephropathy in diabetic rats.

Authors:  P Chen; J Chen; Q Zheng; W Chen; Y Wang; X Xu
Journal:  J Endocrinol Invest       Date:  2012-11-27       Impact factor: 4.256

Review 5.  Neutralization Versus Reinforcement of Proinflammatory Cytokines to Arrest Autoimmunity in Type 1 Diabetes.

Authors:  Ayelet Kaminitz; Shifra Ash; Nadir Askenasy
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

6.  Activation of the transcriptional function of the NF-κB protein c-Rel by O-GlcNAc glycosylation.

Authors:  Parameswaran Ramakrishnan; Peter M Clark; Daniel E Mason; Eric C Peters; Linda C Hsieh-Wilson; David Baltimore
Journal:  Sci Signal       Date:  2013-08-27       Impact factor: 8.192

7.  Otubain 2 is a novel promoter of beta cell survival as revealed by siRNA high-throughput screens of human pancreatic islets.

Authors:  A Beck; Y Vinik; H Shatz-Azoulay; R Isaac; S Streim; G Jona; S Boura-Halfon; Y Zick
Journal:  Diabetologia       Date:  2013-03-21       Impact factor: 10.122

Review 8.  Anti-inflammatory therapy in type 1 diabetes.

Authors:  Bernd Baumann; Heba H Salem; Bernhard O Boehm
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

9.  Inhibition of nuclear factor-κB activation in pancreatic β-cells has a protective effect on allogeneic pancreatic islet graft survival.

Authors:  Roy Eldor; Roy Abel; Dror Sever; Gad Sadoun; Amnon Peled; Ronit Sionov; Danielle Melloul
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

10.  Retinal Protein O-GlcNAcylation and the Ocular Renin-angiotensin System: Signaling Cross-roads in Diabetic Retinopathy.

Authors:  Sadie K Dierschke; Michael D Dennis
Journal:  Curr Diabetes Rev       Date:  2022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.